Arcutis Biotherapeutics Inc
(NAS:ARQT)
$
10.82
0.42 (4.04%)
Market Cap: 1.27 Bil
Enterprise Value: 1.14 Bil
PE Ratio: 0
PB Ratio: 8.08
GF Score: 36/100 
Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 12:00PM GMT
Release Date Price:
$20.44
(-5.06%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Joining us. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research. This is the fireside chat with Arcutis Biotherapeutics. Very happy to have with me CEO, Frank Watanabe. Frank, thanks for joining us.
Todd Franklin Watanabe
Arcutis Biotherapeutics, Inc. - President, CEO & Director
Thanks for being having me.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Of course. Before we get started, I need to read a brief disclosure. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions)
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
With that, let's get started. We have around 30 minutes. Frank, before we jump into any
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers